Sort
10,766 grants matching “checkpoint inhibitor”
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition
$364,015Joanne B Weidhaas · University Of California Los Angeles · R01 · FY2023 · CA
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition
$364,012Joanne B Weidhaas · University Of California Los Angeles · R01 · FY2022 · CA
Evaluation of Immune-based Combinations in Metastatic Prostate Cancer
$364,008Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Novel Therapeutic Approaches for Aggressive Prostate Cancer
$363,999Arthur M Mercurio · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · CA
Impact of Leukemia Microenvironment on Response to Targeted Therapies in AML
$363,916Anupriya Agarwal · Oregon Health & Science University · U54 · FY2021 · CA
Impact of Leukemia Microenvironment on Response to Targeted Therapies in AML
$363,916Anupriya Agarwal · Oregon Health & Science University · U54 · FY2020 · CA
Project 3: Localized microneedle-directed combination immunotherapy for cSCC
$363,863Louis D Falo · University Of Pittsburgh At Pittsburgh · P50 · FY2021 · CA
Checkpoint Kinase Chk1 in Cancer Biology and Therapy
$363,850Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2009 · CA
Checkpoint Kinase Chk1 in Cancer Biology and Therapy
$363,850Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2008 · CA
Checkpoint Kinase Chk1 in Cancer Biology and Therapy
$363,850Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2007 · CA
Checkpoint Kinase Chk1 in Cancer Biology and Therapy
$363,850Tony R. Hunter · Salk Institute For Biological Studies · R01 · FY2010 · CA
Regulation of repetitive elements in cancer by P53 and epigenetic mechanisms
$363,801Katherine B Chiappinelli · George Washington University · R37 · FY2023 · CA
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC
$363,793Andrew B. Sharabi · University Of California, San Diego · R01 · FY2022 · DE
Monocyte promotion of therapy resistance by immune and non-immune mechanisms
$363,713Yi Lin · Mayo Clinic Rochester · R01 · FY2017 · CA
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.
$363,713Richard G Vile · Mayo Clinic Rochester · R01 · FY2023 · CA
Monocyte promotion of therapy resistance by immune and non-immune mechanisms
$363,713Yi Lin · Mayo Clinic Rochester · R01 · FY2020 · CA
Monocyte promotion of therapy resistance by immune and non-immune mechanisms
$363,713Yi Lin · Mayo Clinic Rochester · R01 · FY2016 · CA
Monocyte promotion of therapy resistance by immune and non-immune mechanisms
$363,713Yi Lin · Mayo Clinic Rochester · R01 · FY2018 · CA
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.
$363,713Richard G Vile · Mayo Clinic Rochester · R01 · FY2025 · CA
Mechanistic investigations of microbiome-driven aryl hydrocarbon receptor activity and macrophage function in pancreatic cancer.
$363,672Tracy L McGaha · University Health Network · R01 · FY2023 · CA
Project 1: Decoding, Modeling and Targeting Oncohistones and an Oncohistone-like Protein
$363,562Nada Jabado · Rockefeller University · P01 · FY2021 · CA
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
$363,453Ann Richmond · Vanderbilt University · R01 · FY2021 · CA
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy
$363,450John Tanner Wilson · Vanderbilt University · R01 · FY2020 · CA
Targeting the vasculature to enhance anti-tumor immunity
$363,375Andrew Carl Dudley · University Of Virginia · R01 · FY2021 · CA
Targeting the vasculature to enhance anti-tumor immunity
$363,375Andrew Carl Dudley · University Of Virginia · R01 · FY2020 · CA